These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 26892042)

  • 1. Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis.
    Rossini M; Zanotti R; Orsolini G; Tripi G; Viapiana O; Idolazzi L; Zamò A; Bonadonna P; Kunnathully V; Adami S; Gatti D
    Osteoporos Int; 2016 Aug; 27(8):2411-21. PubMed ID: 26892042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone Disease in Mastocytosis.
    Orsolini G; Viapiana O; Rossini M; Bonifacio M; Zanotti R
    Immunol Allergy Clin North Am; 2018 Aug; 38(3):443-454. PubMed ID: 30007462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zoledronic acid in osteoporosis secondary to mastocytosis.
    Rossini M; Zanotti R; Viapiana O; Tripi G; Idolazzi L; Biondan M; Orsolini G; Bonadonna P; Adami S; Gatti D
    Am J Med; 2014 Nov; 127(11):1127.e1-1127.e4. PubMed ID: 24954632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multimodal therapy for vertebral involvement of systemic mastocytosis.
    Krüger A; Hamann C; Brendel C; Ramaswamy A; Schnabel M; Neubauer A; Hofbauer LC
    Spine (Phila Pa 1976); 2009 Aug; 34(17):E626-8. PubMed ID: 19644322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone involvement and osteoporosis in mastocytosis.
    Rossini M; Zanotti R; Viapiana O; Tripi G; Orsolini G; Idolazzi L; Bonadonna P; Schena D; Escribano L; Adami S; Gatti D
    Immunol Allergy Clin North Am; 2014 May; 34(2):383-96. PubMed ID: 24745681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Denosumab for the Treatment of Mastocytosis-Related Osteoporosis: A Case Series.
    Orsolini G; Gavioli I; Tripi G; Viapiana O; Gatti D; Idolazzi L; Zanotti R; Rossini M
    Calcif Tissue Int; 2017 Jun; 100(6):595-598. PubMed ID: 28229176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment.
    Bayer CM; Beckmann MW; Fasching PA
    Curr Opin Obstet Gynecol; 2017 Feb; 29(1):4-11. PubMed ID: 28002265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis.
    Laroche M; Livideanu C; Paul C; Cantagrel A
    Am J Med; 2011 Aug; 124(8):776-8. PubMed ID: 21787907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Severe therapy refractive osteoporosis : A rare differential diagnosis].
    Gehlen M; Lazarescu AD; Hinz C; Schmidt N; Pfeifer M; Werner M; Weidemann HF; Schwarz-Eywill M; Maier A
    Z Rheumatol; 2016 Sep; 75(7):729-35. PubMed ID: 27193336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new antiresorptive approach to the treatment of fragility fractures: long-term efficacy and safety of denosumab.
    Tarantino U; Celi M; Feola M; Liuni FM; Resmini G; Iolascon G
    Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S65-9. PubMed ID: 24046047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of RANK/RANKL signal transduction pathway: a promising approach for osteoporosis treatment.
    Bai YD; Yang FS; Xuan K; Bai YX; Wu BL
    Med Hypotheses; 2008 Aug; 71(2):256-8. PubMed ID: 18445511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-resorptive therapies for osteoporosis.
    Reid IR
    Semin Cell Dev Biol; 2008 Oct; 19(5):473-8. PubMed ID: 18760372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [[Antiresorptive agents in the treatment of osteoporosis].
    Novak S
    Reumatizam; 2014; 61(2):89-94. PubMed ID: 25427401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
    Josse R; Khan A; Ngui D; Shapiro M
    Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Histological characteristics and prevalence of secondary osteoporosis in systemic mastocytosis. A retrospective analysis of 158 cases].
    Delling G; Ritzel H; Werner M
    Pathologe; 2001 Mar; 22(2):132-40. PubMed ID: 11321729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zoledronate inhibits receptor activator of nuclear factor kappa-B ligand-induced osteoclast differentiation via suppression of expression of nuclear factor of activated T-cell c1 and carbonic anhydrase 2.
    Nakagawa T; Ohta K; Kubozono K; Ishida Y; Naruse T; Takechi M; Kamata N
    Arch Oral Biol; 2015 Apr; 60(4):557-65. PubMed ID: 25601046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic mastocytosis and bone involvement in a cohort of 75 patients.
    Barete S; Assous N; de Gennes C; Grandpeix C; Feger F; Palmerini F; Dubreuil P; Arock M; Roux C; Launay JM; Fraitag S; Canioni D; Billemont B; Suarez F; Lanternier F; Lortholary O; Hermine O; Francès C
    Ann Rheum Dis; 2010 Oct; 69(10):1838-41. PubMed ID: 20570833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skin and bones: systemic mastocytosis and bone.
    Wang M; Seibel MJ
    Endocrinol Diabetes Metab Case Rep; 2023 May; 2023(2):. PubMed ID: 37166908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab and bisphosphonates: different mechanisms of action and effects.
    Baron R; Ferrari S; Russell RG
    Bone; 2011 Apr; 48(4):677-92. PubMed ID: 21145999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients.
    Jobke B; Milovanovic P; Amling M; Busse B
    Bone; 2014 Feb; 59():37-43. PubMed ID: 24211427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.